Neuromuscular Disorder-Targeting Compound 1 |
| Katalog-Nr.GC31288 |
Neuromuscular Disorder-Targeting Compound 1 wird in der Erforschung von neuromuskulÄren Erkrankungen wie Symptomen des Fibromyalgie-Syndroms und des chronischen MÜdigkeitssyndroms verwendet.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 374538-23-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Neuromuscular Disorder-Targeting Compound 1 is used in the research of neuromuscular disorders such as symptoms of fibromyalgia syndrome and chronic fatigue syndrome.
Neuromuscular Disorder-Targeting Compound 1 is used in the research of neuromuscular disorders such as symptoms of fibromyalgia syndrome and chronic fatigue syndrome[1].
[1]. Robertson, David W., et al. TREATMENT OF FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME. WO 2001087308 A1.
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *